Slingshot Insights | Catalyst

Catalyst

Slingshot members are tracking this event:

Gilead (GILD) Announces Top-Line Phase 2 Data for GS-4997 in Diabetic Kidney Disease (DKD)

Source Link:: http://www.gilead.com/news/press-releases/2016/10/gilead-announces-topline-phase-2-results-for-gs4997-selonsertib-in-nonalcoholic-steatohepatitis-nash-pulmonary-arterial-hypertension-pah-and-diabetic-kidney-disease-dkd

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies

Importance

High

Medium

Low

Impact on Stocks

100%

SIGN ME UP
I want to vote! LOG ME IN
Now!

Slingshot Insights Explained

JOIN FOR FREE TODAY

Catalyst Date

Occurred on:

Oct 20, 2016

Related Projects

Don’t see a project related to the catalyst you care about?

Related Keywords Diabetic Kidney Disease, Gs-4997, Selonsertib